HTBA embarks on new growth strategy with Miura Partners’ investment
HealthTech BioActives (HTBA) has welcomed Miura Partners as its new majority shareholder, which will support the company’s growth in Functional Health, Active Pharmaceutical Ingredients, Taste Modulation and Animal Nutrition.
Under its previous owner, The Riverside Company, the manufacturer of citrus flavonoids and active forms of vitamin B12 pursued international expansion and modernization over five years. In the new phase, Miura Partners will drive organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients in health and food.
Miura Partners’ investment marks the third of the Miura Fund IV, which held its final close in 2024 with a size of €475 million (US$507 million).
Jordi Alegre, managing partner at Miura Partners, comments: “We are very pleased with our investment in HTBA, a leader in the strategic natural ingredients sector for the pharmaceutical and nutrition industries, with a strong track record in innovation, growth and sustainability.”
“This investment aligns well with our mid-market buy-out strategy, focusing on industry-leading companies with solid business models, strong growth potential and a top-tier management team.”
Alexandre Valls-Coma, chief executive officer of HTBA, says that the new chapter in the company’s history represents progress and the consolidation of its growth strategy based on innovation and sustainability.
“We remain focused on providing solutions that enhance the health and well-being of people and animals as a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12.”
Expansion strategy
Since 2019, HTBA has increased its annual revenue by 66%, reaching €80 million (US$85 million), and doubled its international workforce to 200 employees.
The new shareholder structure with Miura Partners is “an important milestone for HTBA,” says Valls-Coma.
He adds that the company will continue its mission of unlocking the power of nature through its proprietary processes and high-purity ingredients, with a commitment to sustainability.
“Staying true to these principles has enabled us to enhance the health and well-being of both people and animals for over 40 years and made us a global leader in the manufacturing and distributing flavonoids and active forms of vitamin B12. As we begin our partnership with Miura, we can’t wait to take our ambitious growth plans to the next level.”
Earlier this year, HTBA joined Abolis Biotechnologies to develop a new sustainable method to extract polyphenol compounds. The strategic collaboration aimed to contribute to HTBA’s growth through innovation and sustainability.
The company recently showcased its active forms of vitamin B12 and citrus flavonoids at CPHI 2024 in Milan, Italy, and SupplySide West 2024 in Las Vegas, Nevada, US.
